These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 15837620)
1. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620 [TBL] [Abstract][Full Text] [Related]
2. EGF receptor inhibition: attacks on multiple fronts. Hubbard SR Cancer Cell; 2005 Apr; 7(4):287-8. PubMed ID: 15837615 [TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Li S; Kussie P; Ferguson KM Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813 [TBL] [Abstract][Full Text] [Related]
5. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559 [TBL] [Abstract][Full Text] [Related]
6. Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor. Kim JH; Sim DW; Park D; Jung TG; Lee S; Oh T; Ha JR; Seok SH; Seo MD; Kang HC; Kim YP; Won HS Appl Microbiol Biotechnol; 2016 Dec; 100(24):10521-10529. PubMed ID: 27470143 [TBL] [Abstract][Full Text] [Related]
7. Role of N-glycosylation in EGFR ectodomain ligand binding. Azimzadeh Irani M; Kannan S; Verma C Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782 [TBL] [Abstract][Full Text] [Related]
8. Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. Barta P; Volkova M; Dascalu A; Spiegelberg D; Trejtnar F; Andersson K J Pharmacol Toxicol Methods; 2014; 70(2):145-51. PubMed ID: 25084055 [TBL] [Abstract][Full Text] [Related]
9. Computational modeling of an epidermal growth factor receptor single-mutation resistance to cetuximab in colorectal cancer treatment. Buch I; Ferruz N; De Fabritiis G J Chem Inf Model; 2013 Dec; 53(12):3123-6. PubMed ID: 24219403 [TBL] [Abstract][Full Text] [Related]
11. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973 [TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope. Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468 [TBL] [Abstract][Full Text] [Related]
13. Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site. Talavera A; Mackenzie J; Garrido G; Friemann R; López-Requena A; Moreno E; Krengel U Mol Immunol; 2011 Jul; 48(12-13):1578-85. PubMed ID: 21592580 [TBL] [Abstract][Full Text] [Related]
14. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944 [TBL] [Abstract][Full Text] [Related]
15. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Muller YA; Chen Y; Christinger HW; Li B; Cunningham BC; Lowman HB; de Vos AM Structure; 1998 Sep; 6(9):1153-67. PubMed ID: 9753694 [TBL] [Abstract][Full Text] [Related]
16. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516 [TBL] [Abstract][Full Text] [Related]
17. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629 [TBL] [Abstract][Full Text] [Related]
18. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab. Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124 [TBL] [Abstract][Full Text] [Related]
19. Active and inactive conformations of the epidermal growth factor receptor. Ferguson KM Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003 [TBL] [Abstract][Full Text] [Related]
20. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix. Liang H; Li X; Wang B; Chen B; Zhao Y; Sun J; Zhuang Y; Shi J; Shen H; Zhang Z; Dai J Sci Rep; 2016 Feb; 6():18205. PubMed ID: 26883295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]